Saxena Akshat, Valle Sarah J, Liauw Winston, Morris David L
UNSW Department of Surgery, St George Hospital, Kogarah, New South Wales, Australia.
J Gastrointest Surg. 2017 Aug;21(8):1318-1327. doi: 10.1007/s11605-017-3444-8. Epub 2017 May 30.
There is a paucity of data on the impact of allogenic blood transfusion (ABT) on morbidity and survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
Nine hundred and thirty-five consecutive CRS/HIPEC procedures were performed between 1996 and 2016 at a high-volume institution in Sydney, Australia. Of these, 337(36%) patients required massive ABT (MABT) (≥5 units). Peri-operative complications were graded according to the Clavien-Dindo classification. The association of concomitant MABT with 21 peri-operative outcomes and overall survival (OS) was assessed using univariate and multivariate analyses.
In-hospital mortality was 1.8%. Patients requiring MABT had more extensive disease as reflected by a higher peritoneal cancer index (≥17) (70 vs. 29%, p < 0.001) and longer operative times (≥9 h) (82 vs. 35%, p < 0.001). After accounting for confounding factors, MABT was associated with in-hospital mortality (relative risk (RR), 7.72; 95% confidence interval (CI), 1.35-10.11; p = 0.021) and grade III/IV morbidity (RR, 2.05; 95% CI, 1.42-2.95; p < 0.001). MABT was associated with an increased incidence of prolonged hospital stay (≥28 days) (RR, 1.86; 95% CI, 1.26-2.74; p = 0.002) and intensive care unit stay (≥4 days) (RR, 1.83; 95% CI, 1.24-2.70, p = 0.002). It was also associated with a significant OS in patients with colorectal cancer peritoneal carcinomatosis (RR 4.49; p < 0.001) and pseudomyxoma peritonei (RR, 4.37; p = 0.026), but not appendiceal cancer (p = 0.160).
MABT is an independent predictor for poorer peri-operative outcomes including in-hospital mortality and grade III/IV morbidity. It may also compromise long-term survival, particularly in patients with colorectal cancer peritoneal carcinomatosis.
关于同种异体输血(ABT)对减瘤手术及热灌注化疗(CRS/HIPEC)后发病率和生存结局的影响,相关数据较少。
1996年至2016年期间,在澳大利亚悉尼一家大型机构连续进行了935例CRS/HIPEC手术。其中,337例(36%)患者需要大量ABT(MABT)(≥5单位)。围手术期并发症根据Clavien-Dindo分类进行分级。采用单因素和多因素分析评估同时进行MABT与21种围手术期结局及总生存期(OS)之间的关联。
住院死亡率为1.8%。需要MABT的患者疾病范围更广,表现为腹膜癌指数较高(≥17)(70%对29%,p<0.001)和手术时间更长(≥9小时)(82%对35%,p<0.001)。在考虑混杂因素后,MABT与住院死亡率(相对风险(RR),7.72;95%置信区间(CI),1.35 - 10.11;p = 0.021)和III/IV级发病率(RR,2.05;95% CI,1.42 - 2.95;p<0.001)相关。MABT与住院时间延长(≥28天)(RR,1.86;95% CI,1.26 - 2.74;p = 0.002)和重症监护病房住院时间延长(≥4天)(RR,1.83;95% CI,1.24 - 2.70,p = 0.002)的发生率增加相关。它还与结直肠癌腹膜转移癌患者(RR 4.49;p<0.001)和腹膜假黏液瘤患者(RR,4.37;p = 0.026)的显著OS相关,但与阑尾癌患者无关(p = 0.160)。
MABT是围手术期结局较差的独立预测因素,包括住院死亡率和III/IV级发病率。它也可能影响长期生存,特别是在结直肠癌腹膜转移癌患者中。